Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Outcomes and prognosis news

Show

From To
Spanish study gives reassurance: small HIV blips do not predict treatment failure

A very low viral load (20-49 copies/ml) during HIV therapy does not increase the risk of the subsequent virological failure of treatment (viral load above 200 copies/ml), according

Published
21 September 2016
By
Michael Carter
Life expectancy of people starting HIV therapy differs sharply between high- and middle/low-income countries

There are significant disparities in the life expectancy of HIV-positive people starting combination antiretroviral therapy (cART) between world regions, according to the results of a meta-analysis published in

Published
08 September 2016
By
Michael Carter
Package of prophylaxis against infections reduces the risk of death for people starting HIV treatment very late

A package of enhanced prophylaxis against infections significantly reduced the risk of death in adults and children with advanced HIV disease after starting antiretroviral treatment in a

Published
08 August 2016
By
Keith Alcorn
Atripla three times weekly maintains HIV viral suppression for 24 weeks

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression

Published
05 July 2016
By
Liz Highleyman
Less frequent CD4 and viral load monitoring safe for people doing well on ART

The frequency of routine monitoring for people treated with antiretrovirals with viral suppression can be safely reduced from every three months, to every six months, investigators from

Published
13 June 2016
By
Michael Carter
Big increases in proportion of HIV-positive people in US treated with ART and with viral suppression

The proportion of people living with HIV receiving care in the United States who accessed antiretroviral therapy (ART) and achieved viral suppression increased substantially between 2009 and

Published
10 June 2016
By
Michael Carter
Sub-type C infection does not increase the risk of virologic failure when people are taking tenofovir-containing first-line ART

There is no evidence that HIV-positive people with sub-type C infection have an increased risk of treatment failure when receiving tenofovir-containing regimens, investigators from the UK report in

Published
08 June 2016
By
Michael Carter
Very high levels of drug resistance seen in people experiencing first-line antiretroviral therapy failure in Kenya

A cross-sectional survey of viral load in patients attending the largest HIV clinic in Kenya has shown that after an average of nearly two years

Published
31 May 2016
By
Gus Cairns
Spirituality May Help HIV Patients Survive Longer

Over 17 years, researchers followed HIV-positive men and women who were already in the mid-stage of their disease by the time the study began. They found that people who engaged in spiritual practices and thinking had a greater rate of survival than people who did not—two to four times greater, in fact.

Published
09 May 2016
From
The Atlantic
AIDS Treatment in Haiti Promising for Developing Nations

One of the first groups of HIV patients in a poor country to get free AIDS drugs has about the same survival rate as their closest counterparts in the United States, according to scientists at Weill Cornell Medical College.

Published
19 April 2016
From
The New York Times
← First12345...33Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close